TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06993844: Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors

Sponsor: Ensem Therapeutics · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 233 pts

Competing Trials Overlap

10 Active Trials

Excess Burn Exposure

$8,207,430

Rescue Site Savings

+$5,419,260

Unlock Full NCT06993844 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06993844 Rescue Dossier →